Clinical trial of the efficacy and safety of dipyridamole adjuvant therapy in children with IBD

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100048717

Enrollment

Unknown

Registered

2021-07-13

Start date

2021-07-01

Completion date

Unknown

Last updated

2022-03-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn's disease

Interventions

Two groups:Oral dipyridamole

Eligibility

Sex/Gender

All

Age

3 Years to 18 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for childhood inflammatory bowel disease (European Association of Pediatric Gastroenterology, Hepatology and Nutrition, 2014), with a diagnosis of inflammatory bowel disease (Crohn's disease, ulcerative colitis, inflammatory bowel disease ( unformed)); 2. Men and women are not limited, age 3-18 years old; 3. The platelet count in the peripheral blood routine examination is normal or higher than the normal value (100-300x10^9/l); 4. Child IBD Activity Index (PCDAI or PUCAI)>10.

Exclusion criteria

Exclusion criteria: Unstable vital signs.

Design outcomes

Primary

Measure	Time frame
Endoscopic SES-CD scoring criteria;	—

Countries

China

Contacts

Public ContactGong Sitang

Guangzhou Women and Children's Medical Center

sitangg@126.com+86 18902268811

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026